Author(s): ZHANG Yang, CHEN Wei-an, BI Yong, Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University
Pages: 745-747
Year: 2014 Issue:  5
Journal: Applied Journal of General Practice
Keyword:  Parkinson disease; Cognitive impairment; Screening; Dl-3-butylphthalinde;
Abstract: Objective To investigate the prevalence of cognitive impairment in newly diagnosed Parkinson’s disease( PD) patients,and assess the efficacy of dl-3-butylphthalinde in the treatment of cognitive impairment. Methods Total 120 newly diagnosed PD patients were recruited for the general information. Cognitive functions were evaluated using the minimental state examination( MMSE),and the patients with cognitive impairment were divided into routine group and treatment group randomly. Routine group were given Pramipexole alone,the treatment group were given Pramipexole plus dl-3-butylphthalide. Results 42 in 120 newly diagnosed PD patients( 35%) were accompanied by mild cognitive impairment( PD-MCI),and 14 cases( 11. 7%) were diagnosed as dementia( PDD); Remarkable MMSE score improvement was found in the treatment group,there was a significant difference between the two groups on MMSE assessments on the week 4th and 8th after treatment. Conclusion Many newly diagnosed PD patients have cognitive impairment; dl-3-butylphthalinde should be regarded as an effective medication in the treatment of cognitive impairment in PD patients.